Recent Updates
Recently added Catalysts
SNTI Positive Sentiment

Small-molecule regulated safety switch for improved safety of CAR cell therapies in the brain

Tuesday, October 31, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses a novel small-molecule regulated safety switch designed to enhance the safety of CAR cell therapies specifically for brain applications. This innovation was presented at the SITC Annual Meeting by a team of researchers, highlighting its potential to mitigate risks associated with CAR therapies. The development aims to address safety concerns in the administration of these therapies.
Price reaction · baseline $2.798 (2023-10-31 close) · hit after-hours · 2 other SNTI headline(s) in the window, move may be shared
day 0 close · peak
+3.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Introduction of a safety switch for CAR therapies.
  • Potential to improve safety in brain applications.
  • Involvement of a diverse team of researchers.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+84%
120-day peak, hindsight
Typical move
76.7%
average across 4 past catalysts
Cash runway
~5 mo
High dilution risk
Lead asset
SENTI-202
Phase 1 · AML/MDS

Full Press Release Details

SITC Annual Meeting Rebecca T. Cottman, Vanessa Johnson, Michelle Hung, Yin Yin Chong, Eren Chu, Assen Roguev, Marcus Gainer, Joseph Sperling, Monika Avina, Brett Kiedaisch, Raghav Kannan, Chandra Verma, Chew-Li Soh, Conor McAuliffe, Mark Tomishima, Russell M. Gordley, Timothy K. Lu, and Philip Lee

Frequently Asked Questions

What is the purpose of the new safety switch?

The safety switch aims to improve the safety of CAR cell therapies in brain applications.

Where was the safety switch presented?

It was presented at the SITC Annual Meeting.

Who are the researchers involved in this development?

A diverse team of researchers contributed to this innovation.

ShareAdd on Google
Tags: SNTI Viatris Investor Conferences Healthcare CAR therapies safety switch brain treatment SITC Annual Meeting
Last updated: Oct 31, 2023

Biotech snapshot

Cash runway
$19M liquidity · $2M/mo burn
~5 mo
High dilution risk
Lead asset
SENTI-202Phase 1
AML/MDS →

Catalyst track record

+84%
best trade around SNTI's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for SNTI.

See every catalyst's timing & PoA →